Ligand to Report Fourth Quarter Financial Results on February 17

Rhea-AI Summary

Ligand Pharmaceuticals (NASDAQ: LGND) will announce its fourth quarter 2021 financial results on February 17, 2022, after U.S. market close. A conference call led by CEO John Higgins and other executives will follow at 4:30 p.m. Eastern Time. The call aims to discuss financial results and provide business updates. Interested stakeholders can join the call by dialing (833) 540-1167 in the U.S. and (929) 517-0358 internationally, with conference ID 4832757. A webcast will also be available for live and replay access.

Positive

• Scheduled conference call provides opportunity for stakeholder engagement and clarity on financial performance.

Negative

• None.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2021 financial results after the close of the U.S. financial markets on Thursday, February 17, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.

Conference Call and Webcast Information

What:		Ligand conference call to discuss financial results and provide general business updates
Date:		Thursday, February 17, 2022
Time:		4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Conference Call:		Dial (833) 540-1167 within the U.S.
		Dial (929) 517-0358 outside the U.S.
		Conference ID is 4832757
Webcast:		Live and replay webcast of the call are available here.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Ligand’s OmniAb^® technology platform is a patent-protected transgenic animal platform used in the discovery of fully human monoclonal and bispecific therapeutic antibodies. The Captisol^® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology^® is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Servier, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.

Follow Ligand on Twitter @Ligand_LGND.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005338/en/

Ligand Pharmaceuticals Incorporated

Simon Latimer

investors@ligand.com

(858) 550-7766

Twitter: @Ligand_LGND

LHA Investor Relations

Bruce Voss

bvoss@lhai.com

(310) 691-7100

Source: Ligand Pharmaceuticals Incorporated

FAQ

When will Ligand Pharmaceuticals report its fourth quarter 2021 financial results?

Ligand Pharmaceuticals will report its fourth quarter 2021 financial results on February 17, 2022.

What time is the Ligand Pharmaceuticals conference call on February 17, 2022?

The Ligand Pharmaceuticals conference call is scheduled for 4:30 p.m. Eastern Time on February 17, 2022.

How can I access the Ligand Pharmaceuticals conference call?

You can access the Ligand Pharmaceuticals conference call by dialing (833) 540-1167 within the U.S. or (929) 517-0358 outside the U.S.

Who will be speaking on the Ligand conference call?

The Ligand conference call will feature CEO John Higgins, President and COO Matt Foehr, and CFO Matt Korenberg.

Will there be a webcast of the Ligand Pharmaceuticals conference call?

Yes, there will be a live and replay webcast available for the Ligand Pharmaceuticals conference call.